FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205382892> ?p ?o ?g. }

• W3205382892 endingPage "662" @default.
• W3205382892 startingPage "654" @default.
• W3205382892 abstract "Purpose Rising cancer care expenditures and technological advancement of shorter radiation therapy regimens have drawn significant attention to the use of hypofractionated radiation therapy in clinical care. We examine the costs of hypofractionated whole breast irradiation (HF-WBI) compared with conventional whole breast irradiation (CF-WBI) in the United States and investigate the influences of patient characteristics and commercial insurance on HF-WBI use. Methods and Materials In a retrospective study using private employer-sponsored insurance claims, a pooled cross-sectional evaluation of radiation therapy in patients with commercial insurance was performed from 2008 to 2017. The study population included female patients with early-stage breast cancer treated with lumpectomy and whole breast irradiation. Results A total of 15,869 women received HF-WBI, and 59,328 received CF-WBI. HF-WBI use increased from 2008 to 2017. Community-level factors such as a higher proportion of college graduates and greater mixed racial composition were associated with increased HF-WBI use. Mean insurer-paid radiation therapy expenditures were significantly lower for HF-WBI versus CF-WBI (adjusted difference, $6375; 95% confidence interval, $6147–$6603). Mean patient out-of-pocket expenditure for HF-WBI was $139 less than that for CF-WBI. Geographic variation existed across the United States in HF-WBI use (range, 9.6%-36.2%), with no consistent relationship between HF-WBI use and corresponding average cost differences between HF-WBI and CF-WBI. Conclusions If trends continue, HF-WBI will soon become the dominant form of radiation treatment in the United States. Although HF-WBI represents significant savings to the health care system and individual patients, no evidence indicated that a financial disincentive had slowed adoption of HF-WBI. Therefore, multilevel approaches, including individuals, the community, and health policy, should be used to promote cost-effective cancer care. Innovations to policies on cost-effective radiation therapy treatment might consider non-financial incentives to promote HF-WBI use. Rising cancer care expenditures and technological advancement of shorter radiation therapy regimens have drawn significant attention to the use of hypofractionated radiation therapy in clinical care. We examine the costs of hypofractionated whole breast irradiation (HF-WBI) compared with conventional whole breast irradiation (CF-WBI) in the United States and investigate the influences of patient characteristics and commercial insurance on HF-WBI use. In a retrospective study using private employer-sponsored insurance claims, a pooled cross-sectional evaluation of radiation therapy in patients with commercial insurance was performed from 2008 to 2017. The study population included female patients with early-stage breast cancer treated with lumpectomy and whole breast irradiation. A total of 15,869 women received HF-WBI, and 59,328 received CF-WBI. HF-WBI use increased from 2008 to 2017. Community-level factors such as a higher proportion of college graduates and greater mixed racial composition were associated with increased HF-WBI use. Mean insurer-paid radiation therapy expenditures were significantly lower for HF-WBI versus CF-WBI (adjusted difference, $6375; 95% confidence interval, $6147–$6603). Mean patient out-of-pocket expenditure for HF-WBI was $139 less than that for CF-WBI. Geographic variation existed across the United States in HF-WBI use (range, 9.6%-36.2%), with no consistent relationship between HF-WBI use and corresponding average cost differences between HF-WBI and CF-WBI. If trends continue, HF-WBI will soon become the dominant form of radiation treatment in the United States. Although HF-WBI represents significant savings to the health care system and individual patients, no evidence indicated that a financial disincentive had slowed adoption of HF-WBI. Therefore, multilevel approaches, including individuals, the community, and health policy, should be used to promote cost-effective cancer care. Innovations to policies on cost-effective radiation therapy treatment might consider non-financial incentives to promote HF-WBI use." @default.
• W3205382892 created "2021-10-25" @default.
• W3205382892 creator A5004085226 @default.
• W3205382892 creator A5015502083 @default.
• W3205382892 creator A5047106269 @default.
• W3205382892 date "2022-03-01" @default.
• W3205382892 modified "2023-09-26" @default.
• W3205382892 title "Hypofractionated Radiation Therapy for Breast Cancer: Financial Risk and Expenditures in the United States, 2008 to 2017" @default.
• W3205382892 cites W1830334259 @default.
• W3205382892 cites W1901711706 @default.
• W3205382892 cites W1905159967 @default.
• W3205382892 cites W1987423317 @default.
• W3205382892 cites W1990637325 @default.
• W3205382892 cites W2000445173 @default.
• W3205382892 cites W2025180044 @default.
• W3205382892 cites W2046707738 @default.
• W3205382892 cites W2053860026 @default.
• W3205382892 cites W2054693719 @default.
• W3205382892 cites W2085332543 @default.
• W3205382892 cites W2100025800 @default.
• W3205382892 cites W2103608035 @default.
• W3205382892 cites W2129168200 @default.
• W3205382892 cites W2143899676 @default.
• W3205382892 cites W2168124422 @default.
• W3205382892 cites W2210583157 @default.
• W3205382892 cites W2526851200 @default.
• W3205382892 cites W2528569739 @default.
• W3205382892 cites W2583036852 @default.
• W3205382892 cites W2620389466 @default.
• W3205382892 cites W2789698864 @default.
• W3205382892 cites W2790248051 @default.
• W3205382892 cites W2805705871 @default.
• W3205382892 cites W2954293971 @default.
• W3205382892 cites W2957230050 @default.
• W3205382892 cites W2969465077 @default.
• W3205382892 cites W3017132537 @default.
• W3205382892 cites W3021410191 @default.
• W3205382892 cites W3022700556 @default.
• W3205382892 cites W3086878246 @default.
• W3205382892 cites W3204282379 @default.
• W3205382892 doi "https://doi.org/10.1016/j.ijrobp.2021.10.005" @default.
• W3205382892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34637883" @default.
• W3205382892 hasPublicationYear "2022" @default.
• W3205382892 type Work @default.
• W3205382892 sameAs 3205382892 @default.
• W3205382892 citedByCount "2" @default.
• W3205382892 countsByYear W32053828922022 @default.
• W3205382892 countsByYear W32053828922023 @default.
• W3205382892 crossrefType "journal-article" @default.
• W3205382892 hasAuthorship W3205382892A5004085226 @default.
• W3205382892 hasAuthorship W3205382892A5015502083 @default.
• W3205382892 hasAuthorship W3205382892A5047106269 @default.
• W3205382892 hasBestOaLocation W32053828922 @default.
• W3205382892 hasConcept C121608353 @default.
• W3205382892 hasConcept C126322002 @default.
• W3205382892 hasConcept C143998085 @default.
• W3205382892 hasConcept C144024400 @default.
• W3205382892 hasConcept C149923435 @default.
• W3205382892 hasConcept C2777757722 @default.
• W3205382892 hasConcept C2779572924 @default.
• W3205382892 hasConcept C2908647359 @default.
• W3205382892 hasConcept C44249647 @default.
• W3205382892 hasConcept C509974204 @default.
• W3205382892 hasConcept C530470458 @default.
• W3205382892 hasConcept C71924100 @default.
• W3205382892 hasConcept C99454951 @default.
• W3205382892 hasConceptScore W3205382892C121608353 @default.
• W3205382892 hasConceptScore W3205382892C126322002 @default.
• W3205382892 hasConceptScore W3205382892C143998085 @default.
• W3205382892 hasConceptScore W3205382892C144024400 @default.
• W3205382892 hasConceptScore W3205382892C149923435 @default.
• W3205382892 hasConceptScore W3205382892C2777757722 @default.
• W3205382892 hasConceptScore W3205382892C2779572924 @default.
• W3205382892 hasConceptScore W3205382892C2908647359 @default.
• W3205382892 hasConceptScore W3205382892C44249647 @default.
• W3205382892 hasConceptScore W3205382892C509974204 @default.
• W3205382892 hasConceptScore W3205382892C530470458 @default.
• W3205382892 hasConceptScore W3205382892C71924100 @default.
• W3205382892 hasConceptScore W3205382892C99454951 @default.
• W3205382892 hasFunder F4320306260 @default.
• W3205382892 hasFunder F4320332177 @default.
• W3205382892 hasIssue "3" @default.
• W3205382892 hasLocation W32053828921 @default.
• W3205382892 hasLocation W32053828922 @default.
• W3205382892 hasLocation W32053828923 @default.
• W3205382892 hasOpenAccess W3205382892 @default.
• W3205382892 hasPrimaryLocation W32053828921 @default.
• W3205382892 hasRelatedWork W2059347310 @default.
• W3205382892 hasRelatedWork W2219833176 @default.
• W3205382892 hasRelatedWork W2224319365 @default.
• W3205382892 hasRelatedWork W2417530735 @default.
• W3205382892 hasRelatedWork W2759031936 @default.
• W3205382892 hasRelatedWork W2972384824 @default.
• W3205382892 hasRelatedWork W377899687 @default.
• W3205382892 hasRelatedWork W4322771458 @default.
• W3205382892 hasRelatedWork W4322772323 @default.
• W3205382892 hasRelatedWork W4324144375 @default.
• W3205382892 hasVolume "112" @default.

• next